Serum free and total prostate-specific antigen levels in patients with liver disease

Kılıç, Sahir; Günteki̇n, Erol; Danışman, Ahmet; Kukul, Erdal; Süleymanlar, İnci; Sevük, Metin

doi:10.1016/s0090-4295(98)00393-8

Cited by 14 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, if the magnitude of PSA change is greater in middle‐ and older‐aged men than in younger men, as might be expected based on their likely greater degree of preexisting epithelial cell disruption and amount of PSA secreted, then these larger possible rises might be sufficient to influence both screening and biopsy decisions, and thus might be worth pursuing in future research. Additionally, whether or not noninfectious, inflammatory conditions, such as inflammatory bowel disease, influence serum PSA levels might also be of interest, but these have been examined in only a few small studies of hepatitis and periodontitis . We could not address this question in this study because our original data request was limited to infectious disease and genitourinary ICD‐9‐CM codes consistent with our original hypothesis, and because our de‐identified data can no longer be linked to the master DoDSR file.…”

Section: Discussionmentioning

confidence: 99%

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

et al. 2016

View full text Add to dashboard Cite

Although Epstein-Barr virus has been detected in prostate tissue, no associations have been observed with prostate cancer in the few studies conducted to date. One possible reason for these null findings may be use of cumulative exposure measures that do not inform the timing of infection, i.e., childhood versus adolescence/early adulthood when infection is more likely to manifest as infectious mononucleosis (IM). We sought to determine the influence of young adult-onset IM on the prostate by measuring prostate-specific antigen (PSA) as a marker of prostate inflammation/damage among U.S. military members. We defined IM cases as men diagnosed with IM from 1998 to 2003 (n 5 55) and controls as men without an IM diagnosis (n 5 255). We selected two archived serum specimens for each participant, the first collected after diagnosis for cases and one randomly selected from 1998 to 2003 for controls (index), as well as the preceding specimen (preindex). PSA was measured in each specimen. To explore the specificity of our findings for prostate as opposed to systemic inflammation, we performed a post hoc comparison of other infectious disease cases without genitourinary involvement (n 5 90) and controls (n 5 220). We found that IM cases were more likely to have a large PSA rise than controls (20 ng/mL: 19.7% versus 8.8%, p 5 0.027; 40% rise: 25.7% versus 9.4%, p 5 0.0021), as were other infectious disease cases (25.7% versus 14.0%, p 5 0.020; 27.7% versus 18.0%, p 5 0.092). These findings suggest that, in addition to rising because of prostate infection, PSA may also rise because of systemic inflammation, which could have implications for PSA interpretation in older men.

show abstract

Section: Discussionmentioning

confidence: 99%

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Based upon changes in PSA concentration before and after renal and hepatic circulation, they concluded that the kidney and liver may play a role in the elimination of free PSA (f–PSA) from blood stream. Recently we also demonstrated that a limited liver reserve is sufficient to maintain serum f–PSA and total PSA (t–PSA) levels within normal ranges [6]. …”

Section: Introductionmentioning

confidence: 99%

Do Renal Failure and Hemodialysis Have Any Effect on the Elimination of Free and Total Prostate–Specific Antigen?

Danışman¹,

Kılıç²,

Kukul³

et al. 2000

European Urology

Self Cite

View full text Add to dashboard Cite

“…However, only a few reports have supported this expectation. 17,18 Rather, results revealing no or negative relation between liver disease and serum PSA were predominant. [19][20][21][22][23][24] Some investigators noted that serum PSA levels were not significantly different between healthy men and men with liver cirrhosis or chronic hepatitis.…”

Section: Discussionmentioning

confidence: 95%

“…[19][20][21][22][23][24] Some investigators noted that serum PSA levels were not significantly different between healthy men and men with liver cirrhosis or chronic hepatitis. 17,18 Williams et al found that serum bilirubin and aminotransferases declined significantly after liver transplantation, but the mean serum PSA levels before and after liver transplantation were not different. 18 Other investigators demonstrated that the mean serum PSA level was significantly lower in men with liver cirrhosis compared with healthy men.…”

Section: Discussionmentioning

confidence: 99%

The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population

Yoon

Yang

Kim

et al. 2015

CUAJ

View full text Add to dashboard Cite

Cite as: Can Urol Assoc J 2015;9(11-12):E868-72. http://dx.doi.org/10.5489/cuaj.2395 Published online December 14, 2015 AbstractIntroduction: We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy. Methods: Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (≥2.5 ng/mL) in these men (age 45-75 years, PSA≤10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography. Results: A total of 16 563 men (89.4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of ≥2.5 ng/mL with severe FLD, having a 34.7% lower likelihood (odds ratio 0.653, 95% confidence interval 0.477-0.88; p<0.01) compared to men in the normal group. Conclusions: Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice.

show abstract

Serum free and total prostate-specific antigen levels in patients with liver disease

Cited by 14 publications

References 14 publications

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Do Renal Failure and Hemodialysis Have Any Effect on the Elimination of Free and Total Prostate–Specific Antigen?

The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population

Contact Info

Product

Resources

About

Serum free and total prostate-specific antigen levels in patients with liver disease

Cited by 14 publications

References 14 publications

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection

Do Renal Failure and Hemodialysis Have Any Effect on the Elimination of Free and Total Prostate&ndash;Specific Antigen?

The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population

Contact Info

Product

Resources

About

Do Renal Failure and Hemodialysis Have Any Effect on the Elimination of Free and Total Prostate–Specific Antigen?